Does Ditropan XL (oxybutynin) cause side effects?
Ditropan XL has a dual mechanism of action. Contraction of the smooth muscle of the bladder is stimulated by the release of acetylcholine by the nerves within the bladder and the attachment of the acetylcholine to receptors on the surface of the bladder's muscle cells.
Ditropan XL suppresses involuntary contractions of the bladder's smooth muscle (spasms) by blocking the release of acetylcholine. This is referred to as an "anticholinergic effect." Ditropan XL also directly relaxes the bladder's outer layer of muscle (the detrusor muscle).
Common side effects of Ditropan XL include
- dry mouth,
- urinary tract infection (UTIs),
- blurred vision, difficulty urinating, and local reactions at the application site such as itching and rash with transdermal patch use.
Serious side effects of Ditropan XL include serious hypersensitivity reactions involving swelling of the throat, lips, and tongue.
Drug interactions of Ditropan XL include other drugs with anticholinergic effects, such as diphenhydramine, dimenhydrinate, scopolamine, benztropine, disopyramide, thioridazine, and amitriptyline, because it will likely result in an increased frequency and/or severity of anticholinergic side effects which include
- dry mouth,
- blurred vision,
- urinary retention, and
- an increased heart rate or palpitations.
Combining pramlintide with Ditropan XL may severely reduce bowel movements. Ditropan XL may delay passage of potassium tablets through the digestive system and result in ulceration or narrowing of the small intestine.
No controlled studies of Ditropan XL have been done in pregnant women. The potential benefit of Ditropan XL needs to be weighed against any theoretical harm. It is unknown if Ditropan XL is excreted in human milk. Consult your doctor before breastfeeding.
What are the important side effects of Ditropan XL (oxybutynin) ?
The most common side effects of oxybutynin are
The transdermal patch or gel may also cause local reactions at the application sites such as itching and rash. Transdermal patches or gel cause fewer side effects than the tablets. Serious hypersensitivity reactions involving swelling of the throat, lips, and tongue also may occur.
Ditropan XL (oxybutynin) side effects list for healthcare professionals
The safety and efficacy of Ditropan (oxybutynin chloride) was evaluated in a total of 199 patients in three clinical trials. These participants were treated with Ditropan 5-20 mg/day for up to 6 weeks. Table 3 shows the incidence of adverse events judged by investigators to be at least possibly related to treatment and reported by at least 5% of patients.
Table 3 : Incidence (%) of Adverse Events Reported by ≥ 5% of Patients Using Ditropan (5-20mg/day)
|Body System||Adverse Event||Ditropan|
|Infections and Infestations||Urinary tract infection||6.50%|
|Nervous System Disorders||Dizziness||16.60%|
|Eye Disorders||Blurred vision||9.60%|
|Gastrointestinal Disorders||Dry mouth||71.40%|
|Renal and Urinary Disorders||Urinary Hesitation||8.50%|
The most common adverse events reported by patients receiving Ditropan 5-20 mg/day were the expected side effects of anticholinergic agents. The incidence of dry mouth was dose-related.
In addition, the following adverse events were reported by 1 to < 5% of patients using Ditropan (5-20 mg/day) in all studies.
Metabolism and Nutrition Disorders: fluid retention;
Psychiatric Disorders: confusional state;
Nervous System Disorders: dysgeusia, sinus headache;
Eye Disorders: keratoconjunctivitis sicca, eye irritation;
Vascular Disorders: flushing;
Skin and Subcutaneous Tissue Disorders: dry skin, pruritis;
Renal and Urinary Disorders: dysuria, pollakiuria;
Investigations: blood pressure increased, blood glucose increased, blood pressure decreased;
Injury, Poisoning, and Procedural Complications: fall.
Because postmarketing adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following additional adverse events have been reported from worldwide postmarketing experience with Ditropan:
Psychiatric Disorders: psychotic disorder, agitation, hallucination, memory impairment;
Nervous System Disorders: convulsions;
Eye Disorders: cycloplegia, mydriasis, glaucoma;
Cardiac Disorders: tachycardia, QT interval prolongation;
Gastrointestinal Disorders: decreased gastrointestinal motility;
Skin and Subcutaneous Tissue Disorders: rash, decreased sweating;
Renal and Urinary Disorders: impotence;
Reproductive System and Breast Disorders: Suppression of lactation;
General Disorders and Administration Site Conditions: hypersensitivity reactions, including angioedema with airway obstruction, urticaria, and face edema; rare anaphylactic reactions requiring hospitalization for emergency treatment.
What drugs interact with Ditropan XL (oxybutynin)?
The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index.
Mean oxybutynin chloride plasma concentrations were approximately 3-4 fold higher when Ditropan was administered with ketoconazole, a potent CYP3A4 inhibitor.
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.
Ditropan XL (oxybutynin) is an antispasmodic and anticholinergic drug used to treat urinary bladder spasm. Common side effects of Ditropan XL include dry mouth, constipation, tiredness, headache, diarrhea, urinary tract infection (UTIs), blurred vision, difficulty urinating, and local reactions at the application site such as itching and rash with transdermal patch use. No controlled studies of Ditropan XL have been done in pregnant women. The potential benefit of Ditropan XL needs to be weighed against any theoretical harm. It is unknown if Ditropan XL is excreted in human milk. Consult your doctor before breastfeeding.
Multimedia: Slideshows, Images & Quizzes
Urinary Incontinence in Women: Types, Causes, and Treatments for Bladder Control
Urinary incontinence in women is a common problem. Overactive bladder (OAB), stress incontinence, and urge incontinence can be...
Urinary Incontinence Quiz: Test Your Medical IQ
What is urinary incontinence and why do people develop it? Learn all you need to know with this quiz.
Why Do I Pee So Often? Incontinence & Overactive Bladder
You went to the bathroom to pee just a few minutes ago. Now you need to go again. What's going on? Here are some possible reasons.
Picture of Bladder
The urinary bladder is a muscular sac in the pelvis, just above and behind the pubic bone. See a picture of the Bladder and learn...
Urinary Incontinence: Foods and Drinks That Cause Overactive Bladder
What causes overactive bladder (OAB)? A natural remedy is to avoid caffeine, alcohol, and these foods. Learn the foods and...
Related Disease Conditions
Bladder Infection (Cystitis)
Bladder infection is an infection of the bladder, usually caused by bacteria or, rarely, by Candida. Certain people, including females, the elderly, men with enlarged prostates, and those with chronic medical conditions are at increased risk for bladder infection. Bladder infections are treated with antibiotics, but cranberry products and adequate hydration may help prevent bladder infections.
Overactive Bladder (OAB)
Overactive bladder is a sudden involuntary contraction of the muscle wall of the bladder causing urinary urgency (an immediate unstoppable need to urinate). Overactive bladder is is a form of urinary incontinence. Treatment options may include Kegel exercises, biofeedback, vaginal weight training, pelvic floor electrical stimulation, behavioral therapy, and medications.
Treatment & Diagnosis
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.